We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo WHX Labs Dubai 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Analyzer Monitors Blood Ammonium Levels at POC to Facilitate Quick Medical Decisions

By LabMedica International staff writers
Posted on 04 Nov 2022
Image: The POC device could facilitate monitoring of hereditary and hepatic metabolic disorders (Photo courtesy of UAB)
Image: The POC device could facilitate monitoring of hereditary and hepatic metabolic disorders (Photo courtesy of UAB)

Ammonium is a biomarker used to diagnose a series of rare hereditary metabolic disorders, such as the primary disorders of the urea cycle and different organic acidemias, as well as other metabolic and environmental conditions affecting the liver’s function, which can cause a secondary dysfunction of the urea cycle. Ammonium is also useful in the study and monitoring of different hepatopathies (diseases affecting the normal functioning of the liver) caused by the consumption of alcohol or other drugs, medicines and other environmental factors. In all of these disorders, an excess of ammonium is produced, putting the patient’s health at risk. Values surpassing 200 micromoles per liter of blood are considered severe cases of hyperammonemia (high concentration of ammonium in blood) which can cause irreversible damage to the brain, and can even lead to death, if values surpass 500 micromoles per liter. Therefore, an early diagnosis in real time is crucial to minimizing the impact of a hyperammonemia episode on neurological functions. Currently, patients diagnosed with disorders which include hyperammonemia episodes must periodically be visited at hospital, where a blood sample is taken, which then must be treated an analyzed in the lab.

Now, researchers at the Autonomous University of Barcelona (UAB, Barcelona, Spain) have developed an analyzer that monitors the level of ammonium in the patient’s blood using a decentralized method at the point-of-care, instead of sending blood samples to be analyzed in hospital laboratories, where traditional equipment is used. The new device aims to decentralize the blood ammonium determination, making the analysis possible at smaller healthcare centers with direct blood measurements and no need for previous treatments. This would represent multiplying the number of monitoring sites, simplifying the process and reducing the time needed to take medical decisions.

The device uses a microfluidic platform which includes a potentiometric detection system and a gas separation membrane. In this manner, it is possible to automatically separate the ammonium in the form of ammonia from the rest of the complex matrix of blood, obtaining a selective detection free of any other type of interferences. This guarantees a precise and exact determination of ammonium concentration in whole blood and not in plasma, which is the method conventionally used to analyze this parameter. The research team is preparing a prototype that will function under semi-autonomous conditions. Once the device is ready, it will measure all ammonium samples analyzed with the conventional method and with the new equipment created by researchers.

“Increasing the frequency of blood analyses to determine ammonium levels is of vital importance,” explained UAB researcher Mar Puyol, director of the study. She goes on to say that: “Reducing the excess of ammonium in a patient with hyperammonemia is done by restricting protein intake, using drugs to enhance ammonium elimination, and dialysis and hemofiltration in the most acute cases, so that the evolution of the patient will be more favorable the faster the doctors act, and that can be achieved by using the point-of-care analyzers such as the one we have developed.”

Puyol warns that “hundreds of samples will be necessary before the final prototype of the point-of-care analyzer is validated. The next stage will then be industrializing the device to launch it into the market. There are still several stages before reaching that scenario, but the device is expected to become an economic alternative that can facilitate the monitoring of liver diseases in developing countries as well.”

Related Links:
UAB 

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gel Cards
DG Gel Cards

Channels

Molecular Diagnostics

view channel
Image: The LIAISON NES Group A Strep assay is intended for use on the LIAISON NES POC molecular diagnostics system (Photo courtesy of Diasorin)

Group A Strep Molecular Test Delivers Definitive Results at POC in 15 Minutes

Strep throat is a bacterial infection caused by Group A Streptococcus (GAS). It is a leading bacterial cause of acute pharyngitis, particularly in children and adolescents, and one of the most common reasons... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Pathology

view channel
Image: Sophie Paczesny, M.D., Ph.D and her team have made BIOPREVENT freely available for researchers and clinician to test and learn from (Photo courtesy of Cliff Rhodes)

AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear

Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more